medigraphic.com

2012, Number 3

<< Back Next >>

Rev Hematol Mex 2012; 13 (3)

Main bacteria isolated from patients with acute leukemia (2011)

Cabrera-García Á, Balderas-Delgado C, Castellanos-Sinco H, Olarte-Carrillo I, Martínez-Tovar A, Hernández-Sánchez ML, Collazo-Jaloma J, Martínez-Murillo C, Ramos-Peñafiel CO

Language: Spanish
References: 28
Page: 102-107
PDF size: 448.32 Kb.


ABSTRACT

Background: The frequency of bacteria isolates in patients with febrile neutropenia is low. Escherichia coli, Pseudomonas aeruginosa and the different species of Staphylococcus are the most frequent.
Material and methods: Retrospective, Observational and Prolective study. The results of weekly cultures (nasal cavity, pharynx, blood) of patients with acute leukemia during the induction phase studied.
Results: 67 patients were studied, mostly ALL (n=55). The most frequent bacteria were Gram-positive (56%) [Staphylococcus epidermidis (32%), followed by Gram-negative (Escherichia coli [14.7%]). The main site where bacteria were isolated was the nasal cavity followed by pharynx and blood. The frequency of Pseudomonas aeruginosa was 3% unlike Piperacillin-Tazobactam and Cefepime in which the sensitivity was 85%. For Escherichia coli the main sensitivity were for imipenem, meropenem and amikacin (95, 50 y 85% respectively). All Staphylococci were sensitive to vancomycin (›90%).
Conclusion: Weekly samples strategy increases the frequency of bacterial isolates (86.6%), the nasal cavity being the main site. When we exclude these cases, E coli was the most frequent bacteria. Sensitivity to Piperacillin-Tazobactam, Cefepime and Carbapenems is high which supports its use as first-line treatment in febrile neutropenia.


REFERENCES

  1. Saloustros E, Tryfonidis K, Georgoulias V. Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia. Expert Opin Pharmacother 2011;12(6):851-863.

  2. Bow EJ. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis 2011;24(6):545- 553.

  3. Giebel S, Thomas X, Hallbook H, Geissler K, Boiron JM, Huguet F, et al. The prophylactic use of granulocyte-colony stimulating factor during remission induction is associated with increased leukaemia-free survival of adults with acute lymphoblastic leukaemia: a joint analysis of five randomised trials on behalf of the EWALL. Eur J Cancer 2012;48(3):360-367.

  4. Hammond SP, Baden LR. Antibiotic prophylaxis for patients with acute leukemia. Leuk Lymphoma 2008;49(2):183-193.

  5. Hammond SP, Baden LR. Antibiotic prophylaxis during chemotherapy-induced neutropenia for patients with acute leukemia. Curr Hematol Malig Rep 2007;2(2):97-103.

  6. Fanci R, Leoni F, Longo G. Nosocomial infections in acute leukemia: comparison between younger and elderly patients. New Microbiol.2008; 31(1): 89-96.

  7. Jagarlamudi R, Kumar L, Kochupillai V, Kapil A, Banerjee U, Thulkar S. Infections in acute leukemia: an analysis of 240 febrile episodes. Med Oncol. 2000;17(2):111-116.

  8. Roongpoovapatr P, Suankratay C. Causative pathogens of fever in neutropenic patients at King Chulalongkorn Memorial Hospital. J Med Assoc Thai 2010 ;93(7):776-783.

  9. Poyart C, Morand P, Buzyn A. Etiology of bacterial infections in febrile neutropenic patients: the role of the laboratory in the diagnosis]. Presse Med 2004;33(7):460-466.

  10. Mebis J, Jansens H, Minalu G, Molenberghs G, Schroyens W, Gadisseur A, et al. Long-term epidemiology of bacterial susceptibility profiles in adults suffering from febrile neutropenia with hematologic malignancy after antibiotic change. Infect Drug Resist 2010;3:53-61.

  11. Ng ES, Liew Y, Koh LP, Hsu LY. Fluoroquinolone prophylaxis against febrile neutropenia in areas with high fluoroquinolone resistance--an Asian perspective. J Formos Med Assoc 2010;109(9):624-631.

  12. Segal BH, Freifeld AG. Antibacterial prophylaxis in patients with neutropenia. J Natl Compr Canc Netw 2007;5(2):235-242.

  13. Rahman MM, Khan MA. Levofloxacin prophylaxis to prevent bacterial infection in chemotherapy-induced neutropenia in acute leukemia. Bangladesh Med Res Counc Bull. 2009;35(3):91-94.

  14. de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F. Management of febrile neutropenia: ESMO Clinical Practice Guidelines Ann Oncol 2010;21 S5:v252-256

  15. Ramos-Peñafiel C, Rozzen-Fuller E, León-González M, Martínez-Tovar A, Olarte-Carrillo I, Castellanos- Sinco H, et al. Results of treatment of acute lymphoblastic leukemia in two cohorts of Mexican patients. Rev Med Chile 2011;139:1135-1142.

  16. Bravo D, Blanquer J, Tormo M, Aguilar G, Borrás R, Solano C, et al. Diagnostic accuracy and potential clinical value of the Light Cycler SeptiFast assay in the management of bloodstream infections occurring in neutropenic and critically ill patients. Int J Infect Dis. 2011;15(5):e326-e331.

  17. Jin J, Lee YM, Ding Y, Koh LP, Lim SE, Lim R, Tambyah PA, Hsu LY. Prospective audit of febrile neutropenia management at a tertiary university hospital in Singapore. Ann Acad Med Singapore 2010;39(6):453-459.

  18. Rabagliati B R, Fuentes L G, Orellana U E, Oporto C J, Domínguez M I, Benítez G R, et al. Etiology of febrile neutropenia episodes among cancer patients from Hospital Clinico Universidad Catolica, Santiago-Chile. Rev Chilena Infectol 2009;26(2):106-113.

  19. Frank DN, Feazel LM, Bessesen MT, Price CS, Janoff EN, Pace NR. The human nasal microbiota and Staphylococcus aureus carriage. PLoS One 2010;5(5): e 10598.

  20. Karabiber N. Staphylococcus aereus nasal carriage in the normal population and hospital laboratory personnel. Mikrobiyol Bul 1991;25 (2): 187 – 191

  21. Dossi C MT, Zepeda F G, Ledermann D W. [Nasal carriage of Staphylococcus aureus in a cohort of children with cancer]. Rev Chilena Infectol 2007;24(3):194-198.

  22. Maschmeyer G, Braveny I. Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s.Eur J Clin Microbiol Infect Dis 2000;19(12):915- 925.

  23. Paul M, Yahav D, Bivas A, Fraser A, Leibovici L. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev. 2010;(11):CD005197.

  24. Slavin MA, Lingaratnam S, Mileshkin L, Booth DL, Cain MJ, Ritchie DS, et al. Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee. Intern Med J. 2011;41(1b):102-109

  25. Ng ES, Liew Y, Koh LP, Hsu LY. Fluoroquinolone prophylaxis against febrile neutropenia in areas with high fluoroquinolone resistance--an Asian perspective. J Formos Med Assoc 2010;109(9):624-631.

  26. Rangaraj G, Granwehr BP, Jiang Y, Hachem R, Raad I. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer 2010;116(4):967-973.

  27. Oztoprak N, Piskin N, Aydemir H, Celebi G, Akduman D, Keskin AS, Gokmen A, et al. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital. Jpn J Clin Oncol 2010;40(8):761-767

  28. Huang CC, Wu CJ, Wang LR, Lee HC, Chang CM, Lee NY, Chen TY, Ko WC. Antimicrobial susceptibility of bacteremic isolates from cancer patients with or without neutropenia at a medical center in southern Taiwan. J Microbiol Immunol Infect 2011;44(5):376-381.




2020     |     www.medigraphic.com